Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26148261 | 0.85 | DPP4 (0.40) | JAK2JAK3JAK1 | |
| SCHEMBL19275282 | 0.83 | EPHX2 (0.44) | EPHX2NPY5REPHX1ALDH1A1 | |
| SCHEMBL21214451 | 0.79 | KMT2A (0.47) | JAK2JAK3JAK1 | |
| SCHEMBL26148275 | 0.78 | MEN1 (0.43) | EPHX2JAK2CYP2C9ALDH1A1JAK1 | |
| SCHEMBL18909116 | 0.78 | NPC1 (0.44) | EPHX2NPY5RALDH1A1 | |
| SCHEMBL22030909 | 0.77 | EPHX2 (0.38) | EPHX2NPY5RJAK2PGRCYP2D6 | |
| SCHEMBL24584608 | 0.77 | ALDH1A1 (0.36) | NPY5RALDH1A1 | |
| SCHEMBL21281068 | 0.76 | NPY5R (0.38) | EPHX2NPY5RJAK2PGRCYP2D6 | |
| SCHEMBL17285868 | 0.76 | NMT1 (0.44) | JAK2JAK3ALDH1A1 | |
| SCHEMBL20160547 | 0.76 | JAK2 (0.43) | JAK2JAK3ALDH1A1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155557-B2 | Pyrazolopyrimidine compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20190345165-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017089390-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155557-B2 | Pyrazolopyrimidine compounds and methods of use thereof | JAK2, JAK1, JAK3 | EPHX2 2212/4885NPY5R 1899/4885JAK2 1/4885 |
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | EPHX2 1119/4885NPY5R 2061/4885JAK2 2/4885 |
| US-20190345165-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | EPHX2 2212/4885NPY5R 1899/4885JAK2 1/4885 |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | EPHX2 1730/4885NPY5R 2990/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.